GRAIL, Inc. (BMV:GRAL)
Mexico · Delayed Price · Currency is MXN | Market Cap | 50.51B +110.3% |
| Revenue (ttm) | 2.81B +19.4% |
| Net Income | -7.13B |
| EPS | -185.90 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101 |
| Average Volume | 360 |
| Open | 825.00 |
| Previous Close | 890.00 |
| Day's Range | 825.00 - 825.00 |
| 52-Week Range | 606.20 - 1,828.00 |
| Beta | n/a |
| RSI | 47.50 |
| Earnings Date | May 5, 2026 |
About GRAIL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology... [Read more]
Financial Performance
In 2025, GRAIL's revenue was $147.17 million, an increase of 17.18% compared to the previous year's $125.60 million. Losses were -$408.35 million, -79.85% less than in 2024.
Financial numbers in USD Financial StatementsNews
GRAIL to Present at the 2026 Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management ...
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
GRAIL NASDAQ: GRAL said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who ident...
GRAIL Transcript: Bank of America Global Healthcare Conference 2026
Digital and traditional channels are driving strong self-pay growth, with over 1,300 new physicians added and high retest rates. Key clinical data from a large RCT will be presented at ASCO, while FDA and CMS reviews progress. Operational scale and cost efficiency position the business for broad access and future expansion.
Grail price target lowered to $70 from $82 at Baird
Baird lowered the firm’s price target on Grail (GRAL) to $70 from $82 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results. Published…
Grail price target raised to $56 from $54 at Piper Sandler
Piper Sandler raised the firm’s price target on Grail (GRAL) to $56 from $54 and keeps a Neutral rating on the shares. The firm notes the company delivered Q1 beat…
Grail price target raised to $69 from $65 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Grail (GRAL) to $69 from $65 and keeps a Buy rating on the shares. The firm said they posted…
Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking
Los Angeles, CA, May 06, 2026 (GLOBE NEWSWIRE) -- For 600 years, the cigar industry has remained stagnant, bound by a tradition that ignored the fundamental laws of thermodynamics. Today, El Septimo G...
Grail reports Q1 EPS ($2.29), consensus ($1.96)
Reports Q1 revenue $40.8M, consensus $39.15M. “GRAIL (GRAL) continues to execute commercially, with strong volume growth in Q1. We continue to build new partnerships to support demand and were pleased...
GRAIL Earnings Call Transcript: Q1 2026
Q1 2026 saw 50% test volume growth and 37% screening revenue growth, with strong adoption across providers and digital health. FDA review of Galleri is underway, Salesforce expansion is on track, and full-year revenue guidance is reiterated at 22–32%.
GRAIL Earnings release: Q1 2026
GRAIL released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
GRAIL Quarterly report: Q1 2026
GRAIL has published its Q1 2026 quarterly earnings report on May 5, 2026.
GRAIL Reports First Quarter 2026 Financial Results
Q1 Galleri ® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000 Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platf...
GRAIL to Present at the BofA Securities 2026 Health Care Conference
MENLO PARK, Calif., April 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
GRAIL Proxy statement: Proxy filing
GRAIL filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
GRAIL Proxy statement: Proxy filing
GRAIL filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
GRAIL to Announce First Quarter 2026 Financial Results
MENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fin...
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Prese...
Grail initiated with a Neutral at Mizuho
Mizuho analyst Bradley Bowers initiated coverage of Grail (GRAL) with a Neutral rating and $58 price target Grail is a leader in multicancer early detection testing with its Galleri test…
Grail initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of Grail (GRAL) with a Neutral rating and $54 price target The company holds the largest clinical datasets of any company in the multi-cancer early detection…
Grail announces collaboration with Epic to bring Galleri test to EHR platforms
Grail (GRAL) announced a collaboration with Epic to bring the Galleri multi-cancer early detection test into one of the nation’s most widely used electronic health record platforms, supporting broader...
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient Portal Collaboration With Epic Will Allow Clinicians to Seamlessly Order the G...
Grail, Superpower partner to expand early cancer detection
Superpower announced a strategic partnership with GRAIL (GRAL) to bring members access to the Galleri multi-cancer early detection test. The Galleri test is available as an add-on through the Superpow...
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection
Partnership expands access to breakthrough blood-based cancer screening intoSuperpower's comprehensive health check and personalized plans. SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- Superpower, the...
Grail price target lowered to $75 from $130 at Guggenheim
Guggenheim lowered the firm’s price target on Grail (GRAL) to $75 from $130 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies…
Grail upgraded to Buy from Hold at TD Cowen
TD Cowen analyst Dan Brennan upgraded Grail (GRAL) to Buy from Hold with a price target of $65, down from $114. The firm believes the recent selloff in the shares…